• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 3. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides

Recent Advances in Pyridazine-3-carboxamide (CAS: 5450-54-4) Research: A Comprehensive Review

Pyridazine-3-carboxamide (CAS: 5450-54-4) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties. Recent studies have explored its potential as a key scaffold in the development of novel therapeutic agents, particularly in the areas of oncology, infectious diseases, and neurological disorders. This research brief aims to synthesize the latest findings on pyridazine-3-carboxamide, highlighting its molecular mechanisms, synthetic pathways, and therapeutic applications.

One of the most notable advancements in the study of pyridazine-3-carboxamide is its role as a kinase inhibitor. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is often implicated in cancer progression. Recent in vitro and in vivo studies have demonstrated that pyridazine-3-carboxamide derivatives exhibit potent inhibitory activity against specific kinases, such as EGFR and BRAF, which are frequently mutated in various cancers. These findings suggest that pyridazine-3-carboxamide-based compounds could serve as promising candidates for targeted cancer therapies.

In addition to its anticancer properties, pyridazine-3-carboxamide has shown potential in combating infectious diseases. A 2023 study published in the Journal of Medicinal Chemistry reported that certain pyridazine-3-carboxamide derivatives exhibit strong antimicrobial activity against drug-resistant bacterial strains, including MRSA and ESBL-producing Escherichia coli. The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis and inhibit essential enzymes involved in microbial metabolism.

The synthetic chemistry of pyridazine-3-carboxamide has also seen significant progress. Researchers have developed novel, high-yield synthetic routes that enable the efficient production of pyridazine-3-carboxamide derivatives with diverse functional groups. These advancements have facilitated the exploration of structure-activity relationships (SAR), leading to the identification of optimized compounds with enhanced pharmacological profiles. For instance, a recent patent application disclosed a series of pyridazine-3-carboxamide analogs with improved bioavailability and reduced off-target effects.

Despite these promising developments, challenges remain in the clinical translation of pyridazine-3-carboxamide-based therapeutics. Issues such as metabolic stability, toxicity, and drug-drug interactions need to be addressed through further preclinical and clinical studies. Nevertheless, the growing body of research underscores the potential of pyridazine-3-carboxamide as a valuable scaffold in drug discovery. Future directions may include the development of combination therapies and the exploration of its applications in other therapeutic areas, such as autoimmune diseases and neurodegenerative disorders.

In conclusion, pyridazine-3-carboxamide (CAS: 5450-54-4) represents a versatile and promising compound in the field of chemical biology and medicinal chemistry. Its diverse pharmacological activities, coupled with recent advancements in synthetic methodologies, position it as a key player in the development of next-generation therapeutics. Continued research efforts are expected to unlock its full potential and pave the way for innovative treatment strategies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)